2011 brought you speakers from ITC and regulatory representatives including:

  • Jean-Marie Nicolas, UCB Jean-Marie Nicolas
    Director of ADME
    UCB
  • Oliver Langer, Medical University of Vienna Oliver Langer
    Professor in Radiopharmaceutical Chem
    Medical University of Vienna
  • Robert Elsby, AstraZeneca Robert van Waterschoot
    Laboratory Head DMPK
    Abbott Laboratories
  • Constance Hoefer, Medigene Constance Hoefer
    Head of Non-Clinical DMPK
    Medigene
  • Constance Hoefer, Medigene Prof. Douglas Kell
    Research Chair in Bioanalytical Sciences
    School of Chemistry and Manchester Interdisciplinary Biocentre

Explore and Understand the Forthcoming Regulations in order to Develop Transporter Assays, Identify Substrates, Establish IVIVC and Evaluate their Clinical Implications

February 2012 saw the publication of the FDA’s guidance on drug interaction studies but what does this actually mean for industry?

Join leaders from industry, academia and regulatory bodies to discuss clinically relevant drug transporters: the regulatory advances, the technical innovations and the newest DMPK tools.

We bring you pioneering case studies highlighting the most advance research and development in the transporter field allowing you to overcome the key challenges leading to effective drug development.

Our 2011 industry-wide survey has highlighted that the biggest challenges include:

  • Identifying which transporters to study
  • Understanding regulatory requirements
  • Developing assays and screening techniques
  • Predicting IVIVC and clinical implications from preclinical data

The answer to these problems...?

… Pharma IQ’s 3rd Annual Clinically Relevant Drug Transporters Forum this October.

Praise for previous Pharma IQ events:

“Last year’s event was the best one I have attended, very good agenda, very good speakers and very interesting”
Sanofi
“I learned a lot at this conference-the topics were interesting.”
Janssen

[ Register Now ]